Ototoxicity monitoring as part of risk monitoring in the EHDI system

Jessica Stich-Hennen, Au.D., PASC Doctor of Audiology Specialty Certification in Pediatric Audiology

October 7, 2015

ELKS Hearing and Balance Center

Services provided by St. Luke's

JCIH Position Statements



Services provided by St. Luke's

JCIH 1990 Position Statement

High risk criteria additions:

»Ototoxic medications

»Prolonged mechanical ventilation
 »Physical findings of syndromes
 »Parent/caregiver concerns
 »Head trauma
 »Neurodegenerative disorders
 »Infectious diseases associated with hearing loss

Screening recommendation changes:

»Auditory Brainstem Response measurement, not behavioral testing



JCIH 2000 Position Statement

Recommended ALL infants screened before hospital discharge

Risk monitoring: Audiological testing every 6 months until age 3 years.



Take Care Forward.

JCIH 2007 Position Statement

Expanded definition of targeted hearing loss to include:

 <u>Neural hearing loss (Auditory Neuropathy/</u> <u>Dysynchrony) in infants admitted to the NICU</u>

 Separate protocols for NICU and well baby nurseries:
 NICU babies (>5 days) are to have ABR screening so that neural hearing loss will not be missed



JCIH 2007 Position Statement

Re-admissions

 Infant readmitted in the first month of life and present with conditions, which are associated with potential hearing loss, need a repeat hearing screen prior to discharge.

Monitoring of high risk indicators

 – "Infants with risk factors for hearing loss should have <u>at least one diagnostic evaluation by 24-30</u> <u>months of age."</u>



JCIH 2007 Appendix 2: RISK INDICATORS FOR HEARING LOSS

- □ Caregiver concerns (re: hearing, speech, language, or developmental delay)
- Family history of permanent childhood hearing loss
- Neonatal Intensive Care (NICU) of more than 5 days or any of the following regardless of length of stay: ECMO, assisted ventilation, exposure to ototoxic medications (gentimycin and tobramycin) or loop diuretics (furosemide, Lasix), and hyperbilirubinemia that requires exchange transfusion.
- □ In-utero infections
- Craniofacial anomalies
- Known physical findings associated with a syndrome
- □ Syndromes associated with hearing loss, progressive hearing loss or late-onset hearing loss neurodegenerative disorders
- □ Culture-positive postnatal infections associated with hearing loss
- Head trauma, especially basal skull/temporal bone, requiring hospitalization
- □ Chemotherapy



Extended NICU stay

National Perinatal Research Center (NPIC) (Quality Analytic Services (QAS) ~ made the recommendation regarding NICU stay for JCIH 2007

- Approximately 25% of NICU infants are considered "LOW" risk and discharged by 5 days old.
- The remaining approximately 75% of NICU infants, who are hospitalized for greater than 5 days, are considered the "TARGET" population to rule out neural hearing loss.

**NICU stay of greater than 5 days and exposure to loop diuretics were not associated with increased risk of hearing loss (Kraft et al, 2014)



ECMO treatments

- Expracorporeal Membrane Oxygenation (ECMO)- is an aggressive treatment that is used for the life support in infants with respiratory or cardiopulmonary failure
- Study found receiving aminoglycoside antibiotics cumulative of 14 days or more in the course of ECMO raised the risk of SNHL by 5.56 times



Ototoxicity defined...

medications that can damage the ear, resulting in hearing loss, ringing in the ear, or balance disorders.

Take Care Forward.

Ototoxic Medications

 Over 200 known ototoxic medications (prescriptions and OTC)

Used to treat serious infections, cancer, heart disease

Damage may be temporary or permanent

 Aspirin (temporary)
 Cisplatin (permanent)



Take Care Forward.

Why concern about ototoxicity with infants?



Services provided by St. Luke's

Most frequently occurring risk factors

- Ototoxic Medications (>70%)
- Severe Asphyxia (>50%)
- Mechanical Ventilation less than 5 days (>25%)
- Low birth weight (>20%)
- Parental/Physician concerns (>15%)
- ECMO (>10%)

(Cone-Wesson, et al., 2000; Van Riper & Kileny, 2002, Hall, 2007)



Take Care Forward.

Least frequently occurring risk factors (<10%)

- Hyperbilirubinemia
- Craniofacial anomalies
- Family history
- Congenital infections
- Bacterial meningitis
- Substance abuse (maternal)
- Neurodegenerative disorders

(Cone-Wesson, et al., 2000; Van Riper & Kileny, 2002, Hall, 2007)



14

Frequency of hearing loss among high risk indicators

- Craniofacial anomalies (>50%)
- ECMO treatments (>20%)
- Severe Asphyxia/ Mechanical ventilation (>15%)
- Congenital infections (>15%)
- Family History (>15%)
- Bacterial meningitis (>10%)
- Other risk indicators (<10%)

(Cone-Wesson, et al., 2000; Fligor, 2008; Van Riper & Kileny, 2002, Hall, 2007)

Aminoglycosides

- Introduced in 1940s
- Used to treat serious infections due to multi-drug resistant Gram negative bacteria
- May remain in hair cells for months after application (Aran et al, 1999)
- "...<u>weekly or biweekly monitoring is recommended</u> ideally." "...follow-up testing should also be scheduled a <u>few months</u> after drug discontinuation." (AAA Ototoxicity Monitoring, 2009)



Take Care Forward.

Gentamicin

- Introduced 1963
- Most common aminoglycoside used in NICU
- Low cost
- Effectiveness against most Gramnegative bacteria



ASHA 2010- Evidence Based Systematic Review: Drug-Induced Hearing Loss-Gentamicin

- Systematic literature review (20 studies)
- Reported hearing loss from gentamicin induced cochleototoxicity ranging from 0-58%

 Studies varied in dosing, patient populations, diagnostic testing, diagnostic criteria for hearing loss



ASHA 2010- Evidence Based Systematic Review: Drug-Induced Hearing Loss-Gentamicin

Trends noted in the studies: Frequency of administration did not influence the likelihood of hearing loss Dosing amount did not influence the likelihood of hearing loss



A1555G genetic mutation

- Prezant et al (1993) reported on the genetic mutation A1555G, associated with aminoglycoside deafness
- Estivill et al (1998) reported profound hearing loss without aminoglycoside treatments
- United Kingdom study (2002) found 1 in 206 newborns expressing the mutation
- Texas study (1999) only 1 in 1,161 newborn with mutation



Ototoxicity in preterm infants (Zimmerman E, Lahav A, 2012)

Effects of genetics – Iowa Children's Hospital (Ealy et al 2011) - N=703 (1.8% with mtDNA variant) - No hearing loss Loud noise exposure Animal studies have found potentiating effect between noise and aminoglycosides



Recently published aminoglycoside research

 Designer aminoglycosides prevent cochlear hair cell loss and hearing loss (Huth et al, 2015)

 Aminoglycoside ototoxicity and hair cell ablation in the adult gerbil: A simple model to study hair cell loss and regeneration (Abbas et al, 2015)



Risk Monitoring Program



Services provided by St. Luke's

Goals of risk monitoring program

 Identify infants and children at risk for delayed onset or progressive hearing loss

 Timely diagnostic assessments from a pediatric audiologist

Maintain a monitoring and tracking system in the state EHDI data management system



Risk Monitoring Program





Birthing Hospitals/Birthing Center roles:

- Identify infants who have 1 or more risk indicators
- Provide family with referral to pediatric audiology clinic
- Provide the family with information about risk indicators
- Provide the medical home information regarding risk indicator referral
- Report the infants with risk indicators to state EHDI program



Provide on-site hospital/birthing center training

Provide training annually

 Physicians
 Nurse Managers
 Nurses (Screeners)
 Midwifes

Script for hospital staff

"Your baby has been identified as having a high risk (_____) for a lateonset hearing loss. The recommended protocol for babies with high risk indicators is an audiological evaluation around 9 months of age. We will provide a copy of this referral form to the pediatric audiology center and they will contact you for an appointment."



Idaho EHDI Referral forms

 IDAHO SOUND BEGINNINGS (ISB) Barly Hearing Obtection and intervention Department of Healm and Wether, Intal Toddier Program
 FAX TO (208) 332-7331 Within 5 days

 Complete Form for AI: Refers
 Risks
 Transfers[®]
 Missed
 or incomplete

3. HEARING SCREEN RESULTS: First Screen: R Pass Refer INo Result

Congenital Infection (e.g. T-O-R-C-H) Postnatal Infection (e.g. Meningitis) Craniofacial Anomalies-

____Ototoxic Medications - any amount _____Mechanical Ventilation - any amount _____Parent or Physician Concern _____Head Trauma ____Other_____

L Pass Refer No Result

_____ L 🛛 Pass 🗆 Refer 🔹 No Result

4. RISK ASSESSMENT (check all that apply) For LATER - DISET CHLOHOOD HEARING LOSS:

____Family History of Permanent Hearing Loss <18 yrs of age _____NICU stay >5 days _____Syndrome Associated with HL (e.g. Downs)

(monitoring through age 3 is recommended for most risk factors)

DATE :

8/2012

[Please Press Firmly]

Newborn Hearing Screening

DOB-

Birth Hospital: _____

Leat Pint _____ Gender: □ M □ F

> Pint State: Zin:

> > _____ Text? _____

 Two taby <u>of a page to</u> be varies over. Heaving before about the complete betrained to the second s

1. BABY'S INFORMATION:

Nursery: Weil Baby NICU/8pecial Care Baby's Primary Physiolan/Clinis:

2. CONTACT INFORMATION:

Baby's Med Record #:

Baby's Name: _____Last

Mother's name:____

anantiQuantian:

Alternate Phone/Contact

PARENT/GUARDIAN

(*Transfers only) Receiving Hospital:

Send to: Idaho Sound Beginnings-EHDI, PO Box 83720, Bolse, ID 83720-9815 or Fax: (208) 332-7331

Within <u>5 days</u> of screening or discharge— Distribute copies to: Audiologist- 188 - Hospital - Parent - Physician Within <u>6 days</u> of screening or discharge— Vielow Yellow

Nursing/screening staff will inform you of the final results of the baby's hearing screen and give you a copy of these results. If your baby <u>needs</u> testing or follow-up for rists, you will be given an appointment and/or follow-up information. If you have questions please contait table/o Early Hearing Program, table to guide plenning, at (2001 304-302). Financial Assistance for diagnostic stellar may be available.

These teem informed of my backy hearing screen meaks and offer need for diagonality audious privately learning learning teeters the age of a months (Face) months and a second screen s

have had the opportunity to read this clinic's Notice of Privacy Practices. I understand that this information will not be shared with unauthorized individuals. This authorization expires 36 months from the date signed.

STEP 3: RISK ASSESMENT:

international second second	RISK INDICATORS for LATE-ONSET CHILDHOOD HEARING LOSS: Family History of Permanent Hearing Loss < 18 yrs of age
-	NICU stay >5 days
The surveyor	Syndrome Associated with HL (e.g. Downs)
And	Congenital Infection (e.g. T-O-R-C-H)
A CONTRACTOR OF	Postnatal Infection (e.g. Meningitis)
A CONTRACTOR OF	Craniofacial Anomalies
a second s	Ototoxic Medications - any amount
ACCOUNT OF A	Mechanical Ventilation - any amount
7	Head Trauma Other
	(monitoring through age 3 is recommended for most risk factors)



31



Medical home roles:

- Being familiar with risk factors for delayed onset hearing loss
- Explaining screening results and answer questions for the family
- Encourage risk monitoring follow-up
- Providing family with referral to pediatric audiology clinic







Pediatric audiology center roles:

 Providing appropriate comprehensive diagnostic testing for children with risk factors

- Knowledge of risk factors that have high prevalence of delayed onset hearing loss and require early and more frequent assessments
- Providing documentation regarding evaluation outcomes to state EHDI program


Monitoring in audiology clinic

- 5 audiology clinics
- Southwest Idaho and eastern Oregon
- 20 audiologists





Increasing # of hospital referring for risk indicators

2007 & 2008: 2 HOSPITALS

2009 & 2010: 3 HOSPITALS

2011: 4 HOSPITALS

EKSHEARING & BALANCE CENTER

Take Care Forward.



Take Care Forward.

referrals per high risk indicator



KS HEARING & BALANCE CENTER

40

								Ī	T								
NAME	DOB	MR#	1st ATTEMPT	2nd	3rd	RESULTS	SENT TO EHD	Au.D.	FAM	NEONATAL	UTERC	OTO	CRANIO	SYND	NEURO	HEAD	POST
NAME,	#####	#####	not good-sent	letter		NR-DC	yes	Jess		1		1					
NAME,	#####	####	April Hold are	for 4/2	ms to	WNL	yes	Arpil W				1					
NAME,	#####	####	to Eagle 5/3/1	for 7/1	r 8/24	WNL	yes	Jessica E		1		1					
NAME,	#####	####	i Jan Hold are	1/13/1	/11 lv	NR-DC	yes	Jess				1					
NAME,	#####	####	1 ISB to Namp	07/6/1 <i>°</i>	1 w/Je	WNL	yes	Jess	1								
NAME,	#####	###	pysent to Mer	n in Bo	isefro	care											
NAME,	#####	####	B in July hold.I	11 L VIv	1sen	NR-DC	yes	Jess		1		1					
NAME,	#####	####	B in July hold.I	11 L VIV	1 ser	NR-DC	yes	Jess		1		1					
NAME,	#####	###	h Oct Hold are	B to On	5/10	NR-DC	yes	Jess		1		1					
NAME,	#####	####	11 ISB to Eagl	Forms	to Del	WNL	yes	April W.		1		1					
NAME,	#####	####	B in July hold.I	itario 6	7/08	NR-DC	yes	Jess		1							
NAME,	#####	###	i Jan Hold are	'11 lvm	/21/11	WNL	yes	Shannon		1							
NAME,	#####	####	1 ISB to Boise	jood-s	17/13	SNHL	yes	Jess		1							
NAME,	#####	####				COND	yes	Jenna									
NAME,	#####	####				WNL	yes	Alison									
NAME,	#####	####	Boise	int to se	ched g	REFUSED	yes	Jess									
NAME,	#####	####	oise front offic	#sent	letter	NR-DC	yes	Jess		1							
NAME,	#####	####	Feb Hold are	/11 LVI	11 Ivn	NR-DC	yes	Jess					1				
NAME,	#####	####	March Hold ar	of town	sent	NR-DC	yes	Jess									
NAME,	#####	####	h Oct Hold are	B to On	tario.t	WNL	yes			1		1					
NAME,	#####	#####	h Oct Hold are	B to On	tario.t	COND	yes	Larissa		1		1					
NAME,	#####	####	April Hold are	SB to C	Intario	NR-DC	yes	Jess		1		1					
NAME,	#####	#####	1 ISB to Boise	d 7/15 v	w/Jes	WNL	yes	Jess		1		1					
NAME,	#####	###	1 ISB to Boise	d 7/15 v	w/Jes	WNL	yes	Jess		1		1					
NAME,	#####	###	April Hold are	/11 LV	7-14	WNL	yes	Maria									
NAME,	#####	###	sent to Nici/B	oise.BD)	COND	yes	Jess	1	1		1					
NAME,	#####	###	sent to Nici/B	oise.BD)	WNL	yes	Jess	1	1		1					



41

Tracking outcomes





42



EKSHEARING & BALANCE

43



State EHDI program roles:

 Providing training and support for hospitals, birthing center, physicians, and pediatric audiologists on risk factor

- Providing a method for hospitals, birthing centers and pediatric audiologists to report information regarding infants with risk indicators to the state EHDI program
- Tracking and surveillance of infants with risk factors



Idaho EHDI program





Take Care Forward.

Data collected by referral forms



STEP 3: RISK ASSESMENT:

IDAHO SOUND BEGINI Bariy Hearing Detection and Ir Department of Health and Welfare, Info	NINGS (ISB)	FAX TO (208) 332-7 Within 5 days
Complete Form for All: Refers Ris Newborn Hearing Birth Hospital:	ks□ Transfers [*]	Missed 🗆 or Incomple
Referral Form ("Transfers only) Receiving Hospital:		(Please Pres.
Within <u>5 days</u> of screening or discharge— Distribute copies to: Send to: Idaho Sound Beginninge-EHDI, PO Box 83720, Bo	Audiologist - ISB - White Gold Ise, ID 83720-9815	Hospital - Parent - Phys Pink Green Yell or Fax: (208) 332-7331
L.BASTS INFORMATION: tary test leaves #	3. HEARING Pint Screen: 56 56 56 50 50 50 50 50 50 50 50 50 50	SCREED RESULTS: W Press Parter No. N. Pass Parter No. R Pass Parter No. ESSMENT (mech all hull a ESSMENT (mech all hull a ESSMENT (mech all hull a ESSMENT (mech all hull a ESSMENT) (mech all hull a essential with (mech all hull a mech all hull a essential with (mech all hull a mech all hull a essential with (mech all hull a mech all hull a
Here the region that the sound Region that \mathcal{A}_{1} (10) (34-431). The sound \mathcal{A}_{2} must be also also a probability of the sound Region that the Region the Region that the Region th	annelal Assistance for d uid be completed be- any for speech and ablon delays. Anting testing af approx- atric Audiologist can for diagnostic audiology (h hearing screen, but drikt hearing screen, but drikt o relaces medical or she o release medical (rohice) and physican. I a	Bagnocillo feeting may be available. Audiologist: Phone: Address: Address: Appl: date/time: easing/les/ing before the age of 3 month factors are present (see above), hearing information necessary to comprise an so give permission to be hospital and and in the present on the hospital and and information necessary to comprise an so give permission to be notified and information necessary to comprise an

above listed entities or any other outside entities without parentiguardian consent. I have had the opportunity to read this clinic's Notice of Privacy Practices. I understand that this information will not be shared with unauthorized individuals. This authorization explores 30 months now the date size.end.

IT/GUARDIAN :_____ DATE :_____

RISK INDICATORS for LATE-ONSET CHILDHOOD HEARING LOSS: Family History of Permanent Hearing Loss < 18 yrs of age
NICU stay >5 days
Syndrome Associated with HL (e.g. Downs)
Congenital Infection (e.g. T-O-R-C-H)
Postnatal Infection (e.g. Meningitis)
Craniofacial Anomalies
Ototoxic Medications - any amount
Mechanical Ventilation - any amount
Head Trauma Other
(monitoring through age 3 is recommended for most risk factors)

Prevalence of Infants with a Risk Indicator in ISB 2007-2013 Data





Number of Risk Indicators Reported in ISB 2007-2013 Data





Take Care Forward.

Ototoxic medication



- January 2008-December 2014
- 4701 infants passed newborn hearing screening (Ototoxic medication only)
- 2 with diagnosed with delayed-onset hearing loss
 - 1 unilateral severe to profound
 - 1 bilateral mild to moderately severe



Idaho EHDI: Diagnostic testing recommendations for infants with risk indicators

Idaho Sound Beginnings Best Practice Protocol



Audiology Assessment for Risk Factor Follow- up

"The timing and number of hearing re-evaluations for children with risk factors should be customized and individualized depending on the relative likelihood of a subsequent delayed-onset hearing loss." (JCIH 2007 Position Statement)

Early and more frequent assessment may be indicated for children with: cytomegalovirus (CMV) infection, syndromes associated with progressive hearing loss, neurodegenerative disorders, trauma, culture-positive postnatal infections in association with sensorineural hearing loss; for children who have received ECMO or chemotherapy; and when there is a caregiver concern or a family history of hearing loss (JCIH 2008 clarification)

Recommended Minimum Standards:

Behavioral testing at 9 months of age**

All testing should be ear-specific

Tests included in this evaluation are:

- Family/child history
- \checkmark Otoscopy
- Visual Reinforcement Audiometry for each ear:
 - Minimal Response levels for air conduction: 500, 2000 and 4000 Hz
 - Bone conduction as needed to rule out conductive pathology
 - Speech Awareness Thresholds (SAT)
- Limited Otoacoustic Emissions, DPOAE and/or TEOAE
- Immittance battery:
 - 226 Hz probe tone tympanometry-each ear.
 - Ipsilateral acoustic reflexes at 500, 1000 and 2000 Hz;(can also use broadband noise reflex - normal is less than 80 dB HL)
- ABR testing is indicated, if hearing loss is diagnosed, or if responses to behavioral audiometry are not reliable.

Based on: American Speech-Language-Hearing Association. (2004). Guidelines for the Audiologic Assessment of Children from Birth to 5 Years of Age. [Guideline]. www.asha.org/policy

**The recommendation for the initial risk factor evaluation to be done at 9 months of age is based on the following factors:

- The ease of testing using Visual Reinforcement Audiometry for the child and family, and
- The ability to gather the greatest amount of information quickly with minimal repeat visits, balanced with...
- The ability to identify and address hearing losses and caregiver concerns early enough during the critical "language learning period" to maximize communication skills and minimize speech and language delays. Testing of a 2 year old can also be difficult, time consuming and delays identification.

Idaho Sound Beginnings (EHDI)

Infant Toddler Program, 450 W. State St.FI-5, Boise, ID 83720-0036 (208) 334-0829 (208) 332-7331 FAX Cynthia Carlin, EHDI Project Coordinator -- carlinc@dhw.idaho.gov

Funding Provided By Maternal & Child Health Bureau (MCHB), Health Resources And Services Administration (HRSA)

Risk Indicators Associated with Permanent Congenital, Delayed-onset, or Progressive Hearing Loss in Childhood

- Caregiver concerns regarding hearing, speech, 1. language or developmental delay
- 2. Family history of permanent childhood hearing 1055
- 3. Neonatal intensive care of more than 5 days or any of the following regardless of length of stay: ECMO, assisted ventilation, exposure to ototoxic medications (gentamycin/tobramycin) or loop diuretics (furosemide/Lasix) and hyperbilirubinemia requiring exchange transfusion
- In utero infections: CMV, herpes, rubella, syphilis, and toxoplasmosis.
- Craniofacial anomalies, including those that involve the pinna, ear canal, ear tags, ear pits, and temporal bone anomalies.
- 6. Physical finding, such as a white forelock, that are associated with a syndrome known to include a sensorineural or permanent conductive hearing loss
- 7. Syndromes associated with hearing loss or progressive or late onset hearing loss such as neurofibromatosis, osteopetrosis and Usher syndrome; other frequently identified syndromes including Waardenburg, Alport, Pendred, and Jervell and Lange-Nielson.
- Neurodegenerative disorders, such as Hunter 8 syndrome, or sensory motor neuropathies, such as Friedreich ataxia and Charcot-Marie-Tooth syndrome
- Culture-positive postnatal infections associated with sensorineural hearing loss, including confirmed bacterial and viral (especially herpes viruses and varicella) meningitis.
- 10. Head trauma, especially basal skull/temporal bone fractures that requires hospitalization.
- 11. Chemotherapy

Risk factors **bolded** are considered to have a greater concern for delayed onset hearing loss and monitoring of those children should be more frequent than once following the neonatal period.

> Principles and Guidelines for Early Hearing Detection and Intervention Programs Appendix 2. Joint Committee on Infant Hearing 2007 Position Statement (www.jcih.org)

Idaho EHDI: Diagnosed hearing loss

infants w/hearing loss & HIGH RISK INDICATORS

infants w/hearing loss & NO RISK INDICATORS





Take Gare Forward.

Idaho data (2007-2011) Delayed onset hearing loss

 2.7 infants per 10,000 diagnosed with delayed onset hearing loss with risk indicators

 Those with hearing loss the most frequently reported risk indicators were NICU stay (15 infants), ototoxic medications (13 infants)



of risk indicators reported in infants with hearing loss





Class A: Risk indicators

 In-utero infections (congenital CMV) *Culture Positive postnatal infection (Bacterial and viral meningitis) *Syndromes associated with progressive or delayed onset hearing loss (Neurofibromatosis, Osteopetrosis, Usher Syndrome, Townes-Brock) *Syndromes associated with hearing loss (Down syndrome and Sticklers) *Cleft Lip/Palate *ECMO assisted ventilation *Head Trauma involving basal skull/temporal fracture that requires hospitalization *Chemotherapy treatments *Neurodegenerative disorders or sensory motor neuropathies

If baby passes the newborn hearing screening & has one or more CLASS A risk indicator = Recommendation for diagnostic ABR evaluation with pediatric audiologists by 3 months of age.

Class B: Risk indicators

*Family history of childhood hearing loss *In-Utero Infection (Herpes, Rubella, Syphilis, Toxoplasmosis) *NICU stay of greater than 5 days *Any amount of ototoxic exposure (aminoglycosides) *Any amount of mechanical ventilation *Craniofacial anomalies involving pinna, ear canal, ear pits and temporal bone anomalies

If baby passes the newborn hearing screening & has one or more CLASS B risk indicators = Recommendation for diagnostic pediatric hearing evaluation by 1 year of age.









Things to remember

- Risk monitoring programs need participation from hospital, birthing centers, medical homes, audiology centers, and state EHDI programs
- Training from state EHDI programs is important
- No "gold standard" protocol for risk indicator monitoring (ototoxic medications)
- Data collection is an important



Case #1

4 yr old female Reason for referral: Speech delays Speech therapy twice per week Birth history: 32 weeks gestation (2lb 6oz) NICU stay 1 month Ototoxic medication (Gentamicin) Passed AABR hearing screening In 2004, Idaho did not have risk monitoring program



Audiometry



<u>Speech audiometry</u> SRT at 10 dBHL in each ear

<u>Tympanograms</u> Type As bilaterally

Ipsilateral MEMR Absent bilaterally

Take Care Forward.

DPOAE



65

TEOAE



66

3 years later...

8 years old

- Physician requested audiogram due to previous recommendations
- Mom has no significant hearing or speech concerns, but patient
 - Frequently asks for repetition
 - Listens to TV "very loud"



Audiometry

Speech Audiometry: Word recognition @ 50 dBHL- 84% right, 100% left SRT- 10 dBHL right, 0 dBHL left

Tympanograms: Type A bilaterally

MEMR:

- Ipsilateral left/right present
- contralateral right present
- contralateral left absent



DPOAE



TEOAE



Case #2

- Passed AABR hearing screening
- Born at 35 weeks 6/7 days
- NICU stay less than 5 days
- Referred to audiology for risk indicator monitoring (Ototoxic medications)
- No family history of childhood hearing loss
- No history of otitis media

Audiology Evaluation 9 months old



LEFT	KEY	RIGHT	
X(D)	AIR CONDUCTION (MASKED)	0(Д)	
>()	BONE CONDUCTUION (MASKED)	< ([_])	
ŚF	SOUND FIELD	SF	
A	AIDED	A	
a	COCHLEAR IMPLANT	CI	

er er symmetrik kommense komme

	PHONE RIGHT	PHONE		UNADED	ADED
PREDICTED SRT (PTA)	66	đB	dß	dB	dB
OBTAINED SRIGAT	30	40.	20.	dB	dB
MAXIMUM COMFORT LEVEL	dB	đb	dß	dB	d8
TOLERANCE THRESHOLD	dB	由	¢₽	dB	86
	dŧ	6 8	dB.	d8	48
SDS		*			*
SDSdB HTLQUIET				4	96
202					



Take Care Forward.
OAE tracing



Right: 22-Jan-13:	-: 750-8000 H	Iz Diagnostic Te	st - High Noise:	13A22D01.OAE
-------------------	---------------	------------------	------------------	--------------

L1(dB)	L2(dB)	F1(Hz)	F2(Hz)	GM(Hz)	DP(dB)	NF(dB)	DP-NF(dB)
64.9	55.5	6516	7969	7206	11.5	-20.6	32.1
64.7	55.9	4922	6000	5434	6.4	-25.8	32.2
65.1	56.9	3281	3984	3616	0.7	-9.4	10.1
64.7	56.9	2484	3000	2730	0.5	-14.8	15.3
64.7	56.2	1641	2016	1818	3.2	1.6	1.6
65.3	56.2	1219	1500	1352	7.1	-2.7	9.8



Left: 22-Jan-13: -: 750-8000 Hz Diagnostic Test - High Noise: 13A22D00.OAE

			U 1					
L1(dB)	L2(dB)	F1(Hz)	F2(Hz)	GM(Hz)	DP(dB)	NF(dB)	DP-NF(dB)	
68.3	55.6	6516	7969	7206	-16.4	-28.1	11.7	
68.0	57.8	4922	6000	5434	-20.9	-24.6	3.7	
65.7	56.6	3281	3984	3616	-15.5	-18.8	3.3	
66.1	55.7	2484	3000	2730	-5.7	-11.4	5.7	
64.5	55.3	1641	2016	1818	-8.9	0.4	-9.3	
65.9	55.3	1219	1500	1352	3.0	4.5	-1.5	

ABR evaluation 10 months old



74

Take Care Forward.



Take Care Forward.



Take Care Forward.

ABR eHL



Take Care Forward.

10 months old, 18 months old



Ontario 1182 SW 4th Ave. Ontario OR 97914 p. 541.881.0970 www.elkshearingandbalance.org

LEFT	KEY	RIGHT
X(🗂)	AIR CONDUCTION (MASKED)	O(∆)
> (□)	BONE CONDUCTUION (MASKED)	< ([_])
SF	SOUND FIELD	SF
A	AIDED	A
CI	COCHLEAR IMPLANT	CI

	PHONE RIGHT	PHÔNE	BINALIRAL	UNAIDED	AIDED
PREDICTED SRT (PTA)	dß	d8	dB	dB	d8
OBTAINED SRT/SAT (QUIET)	dß	dB	dB	dß	dß
MAXIMUM COMFORT LEVEL	dB	ď8	dB	dB	dß
TOLERANCE THRESHOLD	dΒ	dB	dB	dB	dB
	dB	dβ	dB	dB	dB
SDS @dB HTLQUIET	%	%	96	%	96
SDS @d8 HTL.QUIET	%	%	96	%	%
\$D5	%	5	96	96	96



. . .

78

Take Care Forward.

3 years old



	R	L	В		R	L	В		R	L	B
AC Unmasked	0	$\underline{\times}$		MCL	M	Μ	M	No Response	2	X	÷

Take Care Forward.





REFERENCES

- American Academy of Audiology Position Statement and Clinical Practice Guidelines: Ototoxicity Monitoring. October 2009.
- ASHA 2015. Ototoxic Medications.
- Antibiotics increase risk of hearing loss in patients with deadly bacterial infections. July 2015. Oregon Health Sciences University.
- Cone-Wesson et. al. (2000). Identification of neonatal hearing impairment: Infants with hearing impairment. *Ear and Hearing, 21, 488-507.*
- Fligor, B. (2008). Hearing outcomes in the most critically ill neonate population. Audiology Today, 20 (5), 9-16.
- http://www.ncham.org
- Hall (2007). New Handbook of Auditory Evoked Potentials.
- Hi-Track data from Idaho Sound Beginnings Program (2007-2015).
- Joint Committee on Infant Hearing (2000). Year 2000 Position Statement: Principles and Guidelines for Early Hearing Detection and Invention Programs.
- Joint Committee on Infant Hearing (2007). Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Invention Programs. <u>Pedatrics</u>, 120, 898-921.
- Kraft et. al. (2014). Risk indicators for Congenital and Delayed-onset hearing loss. Otology and Neurootology.
- The NCHAM book, Chapter 10, Risk monitoring for Delayed-Onset hearing loss.
- Van Riper & Kileny (2002). ABR hearing screening for high-risk infants. Neonatal Intensive Care, 15. 47-54.
- Zimmerman E, Lahav A (2012). Journal of Perinataology, Ototoxicity in preterm infants: effects of genetics, aminoglycosides, and loud environmental noise.